Venetoclax (Venclexta/Venclyxto): A Targeted Therapy for Leukemia – Overview and Commercial Profile
AbbVie
Innovative Drug Developer
Drug Namevenetoclax
CAS：1257044-40-8
Original Research Company: AbbVie
Indications: Leukemia
Product Name:Venclexta(US-Japan),Venclyxto(EU)
FDAApproval Time:2016Year4Month11Day, used for the treatment of chronic lymphocytic leukemia(CLL)Patients and Small Lymphocytic Lymphoma(SLL)Patient.2018Year6Month8Day, approved for the treatment of newly diagnosed or ineligible for chemotherapyAMLPatient Patient.2021Year7Month, ApprovalventlextaIn combination with Azacitidine(azacitidine)A breakthrough treatment regimen for previously untreated intermediate, high, and very high-risk myelodysplastic syndromes(myelodysplastic syndrome)Adult patients.
EMAApproval Time:2016Year12Month4Day, for previous usedel(17p13)TreatedCLLPatient andBPatients with failure of cell receptor signal transduction inhibitors.2021Year5Month, approved by the European Commission, willVenclyxtoIn combination with a hypomethylating agent for newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy(AML)Patient.
PMDAApproval Time:2019Year9Month20Day, for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma).
NMPAApproval Time: 2020Year12Month2Day, in combination with azacitidine for the treatment of patients who are not suitable for intensive induction chemotherapy due to comorbidities, or age75Adult patients aged 60 years or older with newly diagnosed acute myeloid leukemia.
According to the Surveillance, Epidemiology, and End Results (SEER) database,2021Year Estimated to Have61090Example: New cases of leukemia account for all new cancer cases.3.2%, Leukemia is the No.10The most common cancer. The estimated number of deaths is approximately23660People, accounting for all cancer deaths3.9%. Since2006Since the year, the incidence rate of the disease has increased on average every year.0.6%, while the mortality rate decreases on average each year.1.5%。
World Health Organization(WHO)In2016The classification was updated in the year, with several modifications made to the traditional classification of acute leukemia and myeloid neoplasms. Global Cancer Trends ObservatoryGLOBOCANShows that the global cancer incidence rate is474519Example, where North America is67784Example. Every100000The age-standardized rate per person is approximately11,The mortality rate is approximately3.2。
Data Source:NCBI
VenclextaGlobal Sales
2018Year3.44Billion US dollars,2019Year7.92Billion USD,2020Year13.37Billion US dollars,2021Year18.2Billion US dollars,2022Year20.09Billion USD,2023Year1-3Quarter16.99Billion USD.
Summary of Targeted Anticancer Drugs (Small Molecule Drugs)(Containing leukemia treatment drugs)
ReferencesDOI:10.1021/acs.joc.8b02750
ReferencesDOI:10.1021/bk-2019-1332.ch001
ReferencesDOI:10.1021/bk-2019-1332.ch001
ReferencesDOI:10.1021/bk-2019-1332.ch001